type 1 diabetes t1d (Galectin Therapeutics)
86
Structured Review
Galectin Therapeutics
type 1 diabetes t1d
![( A ) The concentration of fasting serum Galectin-3 in healthy controls (HC, n = 132), Ab − FDR ( n = 76), Ab + FDR ( n = 30), and patients with <t>T1D</t> ( n = 234). Data are expressed as median ± range. ( B ) The mRNA expression levels of Galectin-3 in CD14 + monocytes isolated from patients with T1D and HC ( n = 10), calculated using the 2 −△△Ct method. ( C ) The concentration of fasting serum LPS in HC and T1D groups ( n = 56). Data are expressed as median ± range. ( D ) Correlation between serum levels of Galectin-3 and LPS in HC and patients with T1D. ( E to J ) The THP-1 cell line, THP-1–cell induced macrophages, and the RAW 264.7 cell line were treated with LPS (100 ng/ml) or vehicle for 24 hours. The mRNA expression levels of Galectin-3 [(E), (G), and (I)] and the protein concentration of Galectin-3 in the supernatant [(F), (H), and (J)] were measured. Data in (E) to (J) are representative of at least three independent experiments with similar results. Data are expressed as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_7048/pmc12757048/pmc12757048__sciadv.adz7916-f1.jpg)
Type 1 Diabetes T1d, supplied by Galectin Therapeutics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/type 1 diabetes t1d/product/Galectin Therapeutics
Average 86 stars, based on 1 article reviews
Type 1 Diabetes T1d, supplied by Galectin Therapeutics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/type 1 diabetes t1d/product/Galectin Therapeutics
Average 86 stars, based on 1 article reviews
type 1 diabetes t1d - by Bioz Stars,
2026-06
86/100 stars
Images
1) Product Images from "Galectin-3 exacerbates autoimmune diabetes by limiting regulatory T cell differentiation and function"
Article Title: Galectin-3 exacerbates autoimmune diabetes by limiting regulatory T cell differentiation and function
Journal: Science Advances
doi: 10.1126/sciadv.adz7916
Figure Legend Snippet: ( A ) The concentration of fasting serum Galectin-3 in healthy controls (HC, n = 132), Ab − FDR ( n = 76), Ab + FDR ( n = 30), and patients with T1D ( n = 234). Data are expressed as median ± range. ( B ) The mRNA expression levels of Galectin-3 in CD14 + monocytes isolated from patients with T1D and HC ( n = 10), calculated using the 2 −△△Ct method. ( C ) The concentration of fasting serum LPS in HC and T1D groups ( n = 56). Data are expressed as median ± range. ( D ) Correlation between serum levels of Galectin-3 and LPS in HC and patients with T1D. ( E to J ) The THP-1 cell line, THP-1–cell induced macrophages, and the RAW 264.7 cell line were treated with LPS (100 ng/ml) or vehicle for 24 hours. The mRNA expression levels of Galectin-3 [(E), (G), and (I)] and the protein concentration of Galectin-3 in the supernatant [(F), (H), and (J)] were measured. Data in (E) to (J) are representative of at least three independent experiments with similar results. Data are expressed as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.
Techniques Used: Concentration Assay, Expressing, Isolation, Protein Concentration
